Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Integer Holdings Corporation is a medical devices business based in the US. Integer Holdings Corporation shares (ITGR) are listed on the NYSE and all prices are listed in US Dollars. Integer Holdings Corporation employs 7,500 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$93.39|
|52-week range||$54.37 - $101.61|
|50-day moving average||$91.29|
|200-day moving average||$92.55|
|Wall St. target price||$113.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.91|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||3.09%|
|1 month (2021-09-24)||2.45%|
|3 months (2021-07-26)||0.83%|
|6 months (2021-04-26)||-1.79%|
|1 year (2020-10-26)||43.79%|
|2 years (2019-10-25)||25.57%|
|3 years (2018-10-26)||29.51%|
|5 years (2016-10-26)||403.18%|
Valuing Integer Holdings Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integer Holdings Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integer Holdings Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Integer Holdings Corporation shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Integer Holdings Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.63. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integer Holdings Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Integer Holdings Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $197.7 million.
The EBITDA is a measure of a Integer Holdings Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||10.56%|
|Gross profit TTM||$285.7 million|
|Return on assets TTM||2.99%|
|Return on equity TTM||7.75%|
|Market capitalisation||$3 billion|
TTM: trailing 12 months
There are currently 670,581 Integer Holdings Corporation shares held short by investors – that's known as Integer Holdings Corporation's "short interest". This figure is 11.1% up from 603,580 last month.
There are a few different ways that this level of interest in shorting Integer Holdings Corporation shares can be evaluated.
Integer Holdings Corporation's "short interest ratio" (SIR) is the quantity of Integer Holdings Corporation shares currently shorted divided by the average quantity of Integer Holdings Corporation shares traded daily (recently around 116218.54419411). Integer Holdings Corporation's SIR currently stands at 5.77. In other words for every 100,000 Integer Holdings Corporation shares traded daily on the market, roughly 5770 shares are currently held short.
However Integer Holdings Corporation's short interest can also be evaluated against the total number of Integer Holdings Corporation shares, or, against the total number of tradable Integer Holdings Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Integer Holdings Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Integer Holdings Corporation shares in existence, roughly 20 shares are currently held short) or 0.0282% of the tradable shares (for every 100,000 tradable Integer Holdings Corporation shares, roughly 28 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Integer Holdings Corporation.
Find out more about how you can short Integer Holdings Corporation stock.
We're not expecting Integer Holdings Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Integer Holdings Corporation's shares have ranged in value from as little as $54.365 up to $101.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Integer Holdings Corporation's is 1.4238. This would suggest that Integer Holdings Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.